Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Free Cash Flow (2016 - 2025)

Integra Lifesciences Holdings' Free Cash Flow history spans 17 years, with the latest figure at -$5.4 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 125.53% year-over-year to -$5.4 million; the TTM value through Dec 2025 reached -$31.1 million, down 224.39%, while the annual FY2025 figure was -$31.1 million, 224.39% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$5.4 million at Integra Lifesciences Holdings, down from $25.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $84.7 million in Q2 2021 and bottomed at -$40.2 million in Q1 2025.
  • The 5-year median for Free Cash Flow is $23.4 million (2024), against an average of $27.7 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 1352.99% in 2021 before it tumbled 13906.53% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $41.8 million in 2021, then soared by 69.36% to $70.9 million in 2022, then tumbled by 51.73% to $34.2 million in 2023, then crashed by 38.21% to $21.1 million in 2024, then plummeted by 125.53% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Free Cash Flow are -$5.4 million (Q4 2025), $25.8 million (Q3 2025), and -$11.2 million (Q2 2025).